@SentiBio

Outsmarting complex diseases with more intelligent medicines

 South San Francisco, CA
sentibio.com/
Joined June 2016
  • Tweets487
  • Following91
  • Followers2.1K
423Media
Senti Biosciences retweeted
Virtual Investor Co.
@InvestorVirtualJan 14
CEO of $SNTI, Timothy Lu, MD, PhD, highlighted key milestones for Senti Biosciences, including the FDA’s RMAT designation for SENTI-202 and recently presented clinical data from the Company’s ongoing AML trial. Access the CEO Connect segment: vimeo.com/1154109185/abf0a1f… @sentibio

SNTI_CEO_Connect_RMAT Designation

Timothy Lu, MD, PhD, CEO of Senti, discusses its recent news release announcing that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to...

vimeo.com
2
2
791
Senti joined Virtual Investor where Dr. Rajangam, President and Head of R&D, shared what this means for the recommended Phase 2 dose of SENTI-202, its potential first-in-class CAR-NK therapy for AML and other blood cancers. vimeo.com/1109325415/9f2c775… $SNTI @SentiBio

SNTI_WTM_SENTI-202 Dose Selection

Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company’s recently announced recommended Phase 2 dose selection for its...

vimeo.com
2
4
573
Tim Lu, CEO of @sentibio, shares how Senti Bio is pioneering smarter medicines to outsmart complex disease during his feature in the Virtual Investor Summer Spotlight On Demand Conference. Listen to his story here: vimeo.com/1103222002/acd8d39… $SNTI

SNTI_VI_SummerSpotlight

This is "SNTI_VI_SummerSpotlight" by JTC TEAM on Vimeo, the home for high quality videos and the people who love them.

vimeo.com
2
24
62,140
The FDA granted @SentiBio #OrphanDrugDesignation for SENTI-202 for the treatment of #AcuteMyeloidLeukemia. Their CMO, Dr. Rajangam discusses #WhatThisMeans for their development program. vimeo.com/1094341592/504c5e8… #VirtualInvestor #Oncology # Leukemia #AML #CellTherapy

SNTI_WTM_FDA_Orphan_Drug_Designation

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

vimeo.com
9
33
37,076
Dr. Rajangam, President, Head of R&D and CMO of @SentiBio, discussed the positive preliminary Phase 1 data for SENTI-202, in a #VirtualInvestor #WhatThisMeans Segment. Check it out here: vimeo.com/1080513993/cd45a41… $SNTI #CellTherapy #CARNK #AcuteMyeloidLeukemia

SNTI_WTM_Positive_Data_From_SENTI-202

Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for...

vimeo.com
1
2
7
35,088
Senti Bio is set to kick off their first #VirtualInvestor Closing Bell Segment today at 4:00 PM ET. This is your chance to hear a live corporate overview from the $SNTI team—don’t miss it! 🔗 Tune in here: bit.ly/448gZbi #CellTherapy #GeneTherapy #CARNK @SentiBio
3
1
4
12,193
#JoinUs for a live corporate overview tomorrow at 4:00 PM ET in the #VirtualInvestor Closing Bell segment with @SentiBio CEO, Timothy Lu, and Chief Medical Officer, Kanya Rajangam. You won't want to miss it! Register now: bit.ly/42sSaFO $SNTI #CellTherapy #GeneTherapy
2
5
22,053
Senti Bio participated in #VirtualInvestor #KOLConnect featuring Dr. Strickland, Director of Leukemia Research at the Sarah Cannon Research Institute, to discuss the current #AML treatment landscape and highlight the potential of SENTI-202. vimeo.com/1075845562/c9ef87d… $SNTI #CARNK

SNTI_KOL_Connect

Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for the Sarah Cannon Research Institute and Kanya Rajangam, MD,...

vimeo.com
1
4
8
65,292
#Don’tMissOut — @SentiBio is making their debut on the #VirtualInvestor Platform in their first-ever Closing Bell segment on Wednesday, April 23rd at 4:00 PM ET. $SNTI will deliver a live corporate overview. Register now: bit.ly/4jhNtoe #CellTherapy #GeneTherapy #CARNK
4
2
12
46,631
ICYMI: Tune in to our new interview with @timlu and Kanya Rajangam from @SentiBio about intelligent #genecircuit #technology. This #podcast episode was a special collaboration with @ceghadban @bios_community. Listen here: ow.ly/GufG50LtlSS #biotech #syntheticbiology
BIOS@bios_community2 Nov 2022
Builders 🧱 w/ Tim Lu & Kanya Rajangam - Co-Founder & CEO + CMO/CDO @ Senti Biosciences Thanks @timlu & Kanya for sharing your story building @SentiBio! See our episode below... ow.ly/jlNl50Lry9H
2
8
Senti Biosciences retweeted
BIOS@bios_community2 Nov 2022
Builders 🧱 w/ Tim Lu & Kanya Rajangam - Co-Founder & CEO + CMO/CDO @ Senti Biosciences Thanks @timlu & Kanya for sharing your story building @SentiBio! See our episode below... ow.ly/jlNl50Lry9H
1
2
8
Senti Biosciences retweeted
CGTLive®@CGT_Live29 Sep 2022
CGTLive spoke with Marty Geidlin, PhD, Senior vice president, Technical Operations, @SentiBio, at #CARTCR about the company's pipeline and the future of cell therapy. Watch now: ow.ly/se9s50KWnis

Marty Giedlin, PhD, on Advantages of Allogeneic NK Cell Therapy Approaches | CGTlive®

The senior vice president of Technical Operations at Senti Biosciences discussed the company’s NK cell logic-gating platform and allogeneic approach.

cgtlive.com
1
1
Senti Biosciences retweeted
Luke Timmerman@ldtimmerman9 Sep 2022
Designing gene circuits for cell therapy. Tim Lu of @SentiBio is the latest guest on The Long Run. timmermanreport.com/2022/09/…

Designing Gene Circuits For Cell Therapies: Tim Lu on The Long Run - TimmermanReport.com

Today’s guest on The Long Run is Tim Lu. Tim is the co-founder and CEO of South San Francisco-based Senti Biosciences. Senti is working to develop gene circuits for cell therapies. This is about...

timmermanreport.com
1
2
7
Senti Biosciences retweeted
Nasdaq Exchange
@NasdaqExchange24 Jun 2022
Replying to @NasdaqExchange @SentiBio
🧬 @SentiBio is developing next-generation cell and gene therapies engineered with gene circuits, which are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. #NasdaqListed
1
11
Senti Biosciences retweeted
Nasdaq Exchange
@NasdaqExchange9 Jun 2022
Welcome to the @NasdaqExchange family, @SentiBio! 🎉 $SNTI’s mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. 🧬 #NasdaqListed
1
8
3
26
Senti Biosciences retweeted
Leaps by Bayer@LeapsByBayer7 Apr 2022
.@Rakhshita will discuss the question of ‘When Will Cell Therapies Achieve Their Promise?’ with @nabsicle, CEO @CellinoBio, and @timlu, CEO @SentiBio, and Kevin Holden from @Synthego.
2
5
1
11
Senti Biosciences retweeted
Leaps by Bayer@LeapsByBayer7 Apr 2022
We're counting the days to @BuiltWithBio 2022, where Leaps team members and portfolio company CEOs will take the stage, alongside many brilliant investors, founders, and scientists. ​ Explore the program: bit.ly/3LBSXbQ
1
2
5
Did you know❓ Black Americans have twice the incidence of #myeloma as any other race or ethnicity. Our education & outreach initiative, Myeloma Link, connects Black patients and caregivers to trusted, free myeloma information and support 👉 bit.ly/3BsyQch
6
9
October is #LiverCancerAwareness Month. Learning you have liver cancer can be terrifying. Know you aren't alone. Connect with us today, with the links to our website and Liver Cancer Facebook Group our bio, or you can call us M-F 9 AM - 5 PM EST at 1-800-465-4837 #LiverCancer
8
1
10
Senti Biosciences retweeted
Thermo Fisher
@thermofisher21 Sep 2021
Accelerating #precisionmedicine starts with having access to the right technology when it’s needed. We have expanded our portfolio to empower our customers to reach new goals in cancer research, cell & gene therapy development, and #raredisease research. ow.ly/te3N50GdLCu
6
1
10
Load more